Related Articles
Stopping GLP-1 Receptor Agonists… Why And How To Plan An “Exit Strategy” For Your Patients
Read the full article here
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…
Eye Health, My Health | National Eye Institute
Eye Health, My Health is NEI’s eye health campaign for Black/African American communities. This campaign promotes eye health as an important part of overall health.
Novant, Community Health Systems hit back at FTC in deal lawsuit
The health systems allege that Novant’s $320 million proposed acquisition of two North Carolina hospitals would not stifle competition, as the Federal Trade Commission claims.
National Advisory Council for Healthcare Research and Quality: Request for Nominations for Members
The National Advisory Council for Healthcare Research and Quality (the Council) advises the Secretary of HHS (Secretary) and the Director of the Agency for Healthcare…
Validate User
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
Newborn Screening For Lysosomal Disorders
Ozlem Goker-Alpan, MD, Founder and CMO of LDRTC, discusses the importance of newborn screening for lysosomal disorders.
AMG 509’s Potential in Prostate Cancer Therapy – Michael Morris
Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal…
Quiz of the Month – April 2024 – JBJS Clinical Classroom
The JBJS Quiz of the Month is a collection of 10 relevant questions from each orthopaedic subspecialty. The questions are drawn from JBJS Clinical Classroom,…
